Results 131 to 140 of about 54,528 (266)

Assessment of subclinical LV myocardial dysfunction in T2DM patients with diabetic peripheral neuropathy: a cardiovascular magnetic resonance study [PDF]

Xueming Li, Ke Shi, Jiang Li, Jing Wang, Wei‐Feng Yan, Yue Gao, Mengting Shen, Rui Shi, Ge Zhang, Xiaojing Liu, Yingkun Guo, Zhi‐gang Yang   +11 more
openalex   +1 more source

Oral Treatment of Chronic Peripheral Diabetic Neuropathy [PDF]

, 2006
MITCHEL L. ZOLER, MIRIAM E. TUCKER
openalex   +1 more source

Insulin therapy DE‐intensificAtion with iGlarLixi: A phase 4, open‐label, parallel‐group randomised controlled trial

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To evaluate the efficacy and safety of transitioning from multiple daily injections (MDIs) insulin regimen to once‐daily, fixed‐ratio combination of basal insulin analog glargine 100 U/mL and a glucagon‐like peptide 1 receptor agonist lixisenatide (iGlarLixi) in people with type 2 diabetes (PwT2D). Materials and Methods Insulin therapy DE‐
Peter Novodvorský, Lenka Thieme, Ivana Laňková, Štěpánka Franková, Alica Veselá, Emil Záhumenský, Tomáš Edelsberger, Marie Löblová, Ondřej Žižka, Miroslav Vytasil, Felipe Lauand, Mireille Bonnemaire, Filip Hrubý, Miloš Mráz, Martin Haluzík   +14 more
wiley   +1 more source

Frailty Prediction Model for Elderly Diabetic Peripheral Neuropathy Patients. [PDF]

Diabetes Metab Syndr Obes
Xie X, Huang Y, Wang Y, Chen W, Liang X, Xiong C, Zou X.   +6 more
europepmc   +1 more source

Association between glucagon‐like peptide‐1 receptor agonists and risk of dementia in older adults with type 2 diabetes: A target trial emulation

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aim Type 2 diabetes (T2D) is associated with increased dementia risk, but comparative data across newer glucose‐lowering therapies remain limited. We examined whether the initiation of GLP‐1 receptor agonists (GLP‐1 RAs) was associated with incident dementia compared with DPP4 inhibitors (DPP4is) and SGLT2 inhibitors (SGLT2is) in older adults ...
Ting Zhou, Huilin Tang, Bingyu Zhang, Dazheng Zhang, Yiwen Lu, Lu Li, Jiajie Chen, Yong Chen, David A. Asch, Yong Chen   +9 more
wiley   +1 more source

Therapeutic targets in diabetic peripheral neuropathy: heat shock proteins. [PDF]

Front Endocrinol (Lausanne)
Yin C, Lv J, Huang S, Lang C, Zhao Y, Wang G, Kan J, Wang X.   +7 more
europepmc   +1 more source

Examination of Questionnaire Items regarding Diabetic Peripheral Neuropathy in Epalrestat-treated Patients and Their Usefulness in the Treatment of This Disorder — Influence on Treatment Course

, 2009
Atsuo Ito, Reiko Ishii‐Nozawa, Chikao Ibuki, Hirotsugu Atarashi, Hirokuni KATAOKA, Koichi Takeuchi   +5 more
openalex   +2 more sources

Impact of Educational Self-efficacy Enhancement Program on Quality of Life, Pain Management, Self-efficiency Behaviors, and Its Impact of Satisfaction Among Adult Diabetic Patients With Peripheral Neuropathy Pain [PDF]

, 2020
Jawad Ahmad Abu-Shennar, Nurhan Bayraktar   +1 more
openalex   +1 more source

Long‐acting insulin analogues and the risk of diabetic nephropathy among patients with type 2 diabetes: A population‐based cohort study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims The risk of diabetic nephropathy among patients with type 2 diabetes (T2D) can be reduced through optimal glycaemic control. It is not known if the pharmacological properties of long‐acting insulin analogues may reduce the risk of diabetic complications compared with neutral protamine Hagedorn (NPH) insulin.
Julia Brillinger, Christopher Filliter, Shahrzad Salmasi, Estefania Zapata‐Bravo, Robert W. Platt, Oriana H. Y. Yu, Kristian B. Filion   +6 more
wiley   +1 more source

Complementary Therapies of Diabetic Peripheral Neuropathy and Intermittent Claudication. [PDF]

Healthcare (Basel)
Ng SY.
europepmc   +1 more source